Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
  • Platform
  • Pipeline
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Connect

In The News

To view the webinar replay of “PRECISE-AD Phase 1b Blinded Interim Data Analysis"  Click Here

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Jun 23, 2026

Bio Spectrum | Can Precision Antibodies Deliver a Safer Future for Alzheimer's Patients?

May 11, 2026

Inside Precision Medicine - Stopping Neurodegeneration in Place with Vaccines

Oct 5, 2022

The ALS Curveball, Part II

Oct 5, 2022

The ALS Curveball, Part I

Aug 2, 2022

New Collaborative Research Grant will Support the Development of a Vaccine for Misfolded Protein Diseases

Jul 18, 2022

A Tale of Tangles We Weave, Chapter 4

Jul 14, 2022

ProMIS rings Nasdaq closing bell, July 13, 2022

Mar 17, 2022

A Tale Of Tangles We Weave

Jan 11, 2022

Stimulating the Next Generation of AD Treatment

Oct 5, 2021

Funding boost expands MND research in our region

rss_feed RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • arrow_forward
Linkedin Twitter
©2026 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy

Disclaimer

All statements and expressions are the sole opinion of the company and are subject to change without notice.  The Company is not liable for any investment decisions by its readers or subscribers.  It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies.  The information contained herein has been provided as an information service only.  The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained.  Investors are cautioned that they may lose all or a portion of their investment in this or any other company.

Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended.  Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements".  Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as "expects", "will", "anticipates", "estimates", "believes", or by statements indicating certain actions "may", "could", "should" or "might" occur.